Biotechnology intellectual property law in GLMZ has evolved from the pre-2150 patent framework into something its architects might not recognize — a system in which genetic sequences, modified cellular architectures, and even certain neurochemical profiles can be proprietary assets subject to licensing, enforcement, and inheritance. The foundational change came with the Biological Innovation Sovereignty Act of 2161, which extended intellectual property protection to 'novel biological configurations produced through deliberate technical intervention,' a definition broad enough to cover gene therapies, synthetic tissue architectures, and — controversially — the second-generation offspring of individuals who received heritable genetic modifications under a licensed protocol.

Helios Biopharma holds the largest portfolio of biological IP in the Meridian region: 4,200 registered sequence patents, 890 cellular architecture protections, and 14 'phenotypic expression licenses' — a category covering specific physical or cognitive traits produced by their proprietary gene therapies. The phenotypic expression license is the most contested legal instrument in current biotech IP law. Under the Biological Innovation Sovereignty Act's 'derivative expression' provision, if a licensed gene therapy produces a heritable trait, the corponation retains a licensing interest in that trait's expression in subsequent generations. Helios has issued 340 'derivative expression notices' to the children and grandchildren of original therapy recipients, asserting a royalty interest in their biological inheritance. Approximately 60 of these cases are currently in litigation, primarily in the Meridian Arbitration Chamber.

The counter-framework is the Genetic Commons Doctrine, a legal theory developed by scholars at the Calumet Institute and argued by a small number of specialist attorneys. The Doctrine holds that heritable traits, once expressed in a living person, become part of that person's constitutive biology and cannot be subject to ongoing proprietary claims under either the Biological Innovation Sovereignty Act or the older patent framework. No Meridian court has adopted the Doctrine as binding precedent, though a 2197 dissenting opinion by Arbiter Yolanda Chukwu in the case Helios Biopharma v. Osei-Bonsu cited it extensively and called the derivative expression provision 'a claim of ownership over persons dressed in the language of property law.'

For individuals operating in the gray-market gene modification subculture — the underground clinics and sequence-sharing networks documented elsewhere — intellectual property law operates as an instrument of criminalization rather than protection. Possession of a patented sequence without a license is treated as infringement regardless of how the sequence was obtained, including cases in which individuals were born with it. The Biological Enforcement Division, a joint unit of the Meridian Civic Authority and the Corponation IP Consortium, conducted 1,400 sequence audits in 2199, the majority targeting residents of the Pilsen Corridor and the South Shore Mesh. Of these, 220 resulted in civil infringement filings; 18 resulted in criminal referrals for 'unlicensed biological operation.'